<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00497172</url>
  </required_header>
  <id_info>
    <org_study_id>CRDIT 00-02/02</org_study_id>
    <nct_id>NCT00497172</nct_id>
  </id_info>
  <brief_title>Diabetes Drug Eluting Sirolimus Stent Experience in Restenosis Trial</brief_title>
  <acronym>DESSERT</acronym>
  <official_title>An Italian Multicenter, Randomized, Single Blind Study of the Sirolimus Eluting Stent in the Treatment Of Diabetic Patients With De Novo Coronary Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cordis Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to assess the safety and effectiveness of the&#xD;
      Sirolimus-eluting stent CYPHERTM and/or updated version in reducing angiographic in-stent&#xD;
      late loss in de novo native coronary lesions of diabetic patients as compared to the bare&#xD;
      metal Bx SONIC balloon-expandable stent.&#xD;
&#xD;
      The secondary objective is to assess cost-effectiveness expressed in incremental cost/life&#xD;
      year gained or cost/quality adjusted life year gained at different time points (8 months, 1&#xD;
      year).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter (11 centers), prospective, randomized single blind study. This study&#xD;
      has a 2-arm design assessing the safety and effectiveness of the Sirolimus-eluting stent&#xD;
      CYPHERTM and/or updated version to the bare metal Bx SONICTM stent. A total of 250 patients&#xD;
      will be entered in the study and will be randomized on a 1:1 basis. Patients who meet the&#xD;
      eligibility criteria will be either randomized to the Sirolimus-eluting stent or the bare&#xD;
      metal Bx SONIC stent. The investigator cannot be blind because the outer appearance of the&#xD;
      system for the implant of the Sirolimus-eluting stent differs from that of the bare metal&#xD;
      stent and will therefore immediately be recognized by the surgeon. However the patient will&#xD;
      not know which stent will be implanted. Patients will be followed at 30 days, 9 and 12 months&#xD;
      post-procedure, with all patients undergoing repeat angiography at 8 months. Additionally,&#xD;
      medical costs associated with the index hospitalization and length of stay, and repeat&#xD;
      hospitalizations and costs associated with other relevant medical resource use during the 1&#xD;
      year follow-up period will be collected and analyzed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>in-stent LL</measure>
    <time_frame>8-month post-procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>1, 9, and 12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion or target vessel revascularization</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>drug-eluting stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bare-metal stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CYPHER Sirolimus-eluting stent</intervention_name>
    <description>drug-eluting stent</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bx SONIC bare metal stent</intervention_name>
    <description>bare-metal stent</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient must be ≥ 18 years of age;&#xD;
&#xD;
          2. Female of childbearing potential must have a negative pregnancy test within 7days of&#xD;
             enrollment and utilize reliable birth control for eight months after enrollment;&#xD;
&#xD;
          3. Patients with IDDM (Type I) treated for at least 3 months with documented HbA1c, or&#xD;
             NIDDM (Type II) treated with oral antidiabetics for at least 3 months;&#xD;
&#xD;
          4. Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society&#xD;
             Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald&#xD;
             Classification B&amp;C, I-II) OR patients with documented silent ischemia OR patient with&#xD;
             previous (&gt;24 hours) myocardial infarction with documented residual ischemia and/or&#xD;
             viable myocardium;&#xD;
&#xD;
          5. Single or double stent treatment of de novo lesion in a major coronary artery in&#xD;
             patients with single or multi-vessel disease; patients with multi-vessel disease can&#xD;
             be included only if a maximum of two vessels require treatment with a maximum of three&#xD;
             lesions in total, no more than two lesions per vessels. The two lesions in a single&#xD;
             vessel must be &gt;10 mm apart (visual estimate) and must be treated with the assigned&#xD;
             stent.&#xD;
&#xD;
          6. Target vessel diameter at the lesion site is ≥ 2.50mm and ≤ 3.5mm in diameter (visual&#xD;
             estimate);&#xD;
&#xD;
          7. Target lesion is ≥ 13mm and ≤ 25mm in length (visual estimate);&#xD;
&#xD;
          8. Target lesion stenosis is &gt;50% and &lt;100% (visual estimate);&#xD;
&#xD;
          9. At least TIMI II coronary flow;&#xD;
&#xD;
         10. Acceptable candidate for coronary artery bypass surgery (CABG);&#xD;
&#xD;
         11. Patient is willing to comply with the specified follow-up evaluation;&#xD;
&#xD;
         12. Patient must provide written informed consent prior to the procedure using a form that&#xD;
             is approved by the local Ethics Committee;&#xD;
&#xD;
         13. Patient can be pretreated with aspirin and clopidogrel or, alternatively, aspirin&#xD;
             alone plus a loading dose of 300 mg of clopidogrel before procedure completion in case&#xD;
             of urgent PCI, and GPIIb IIIa inhibitors (Tirofiban or Abciximab)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented&#xD;
             total CK &gt;2 times normal within the preceding 24 hours and the CK and CK-MB enzymes&#xD;
             remains above normal at the time of treatment;&#xD;
&#xD;
          2. Unprotected left main coronary disease with ≥50% stenosis;&#xD;
&#xD;
          3. Significant (&gt;50%) stenoses proximal or distal to the target lesion that might require&#xD;
             revascularization or impede runoff;&#xD;
&#xD;
          4. Have a target lesion in an arterial or venous by-pass graft;&#xD;
&#xD;
          5. Calcified lesion which cannot be successfully predilated;&#xD;
&#xD;
          6. Documented left ventricular ejection fraction ≤ 30%;&#xD;
&#xD;
          7. TIMI 0-I coronary flow ;&#xD;
&#xD;
          8. Impaired renal function (creatinine &gt; 3.0 mg/dl) at the time of treatment;&#xD;
&#xD;
          9. Pretreatment with devices other than balloon angioplasty;&#xD;
&#xD;
         10. Target lesion has excessive tortuousity or angulation (&gt;45°) which makes it unsuitable&#xD;
             for stent delivery and deployment;&#xD;
&#xD;
         11. Target lesion involves bifurcation including a diseased side branch ≥2 mm in diameter&#xD;
             (either stenosis of both main vessel and major branch or stenosis of just major&#xD;
             branch) that would require side branch stenting;&#xD;
&#xD;
         12. Prior stent within 5mm of target lesion;&#xD;
&#xD;
         13. Direct Stenting;&#xD;
&#xD;
         14. Recipient of heart transplant;&#xD;
&#xD;
         15. Patient with a life expectancy less than 12 months;&#xD;
&#xD;
         16. Known allergies to the following: aspirin, clopidogrel bisulfate (Plavix), heparin and&#xD;
             GPIIb IIIa inhibitors (Tirofiban or Abciximab) stainless steel, contrast agent (that&#xD;
             cannot be managed medically), or sirolimus;&#xD;
&#xD;
         17. Recent (6 months) cerebrovascular accidents or intracranial hemorrhage;&#xD;
&#xD;
         18. Any significant medical condition which in the investigator.s opinion may interfere&#xD;
             with the patient.s optimal participation in the study;&#xD;
&#xD;
         19. Currently participating in an investigational drug or another device study;&#xD;
&#xD;
         20. Intervention of another lesion has occurred within 6 months before the index&#xD;
             procedure;&#xD;
&#xD;
         21. In the investigator.s opinion, the lesion is not suitable for stenting.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A. Maresta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda USL Ravenna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda USL Ravenna - Ospedale santa Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <zip>48100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <study_first_submitted>July 4, 2007</study_first_submitted>
  <study_first_submitted_qc>July 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2007</study_first_posted>
  <last_update_submitted>February 3, 2010</last_update_submitted>
  <last_update_submitted_qc>February 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Hans-Peter Stoll</name_title>
    <organization>Cordis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

